Abstract：Objective To observe the influence of Capecitabine and Oxaliplatin on serum tumor marker levels in patients with advanced colorectal cancer.Methods A total of 85 patients with advanced colorectal cancer treated in our hospital from June2017 to May 2019 wereselected and divided intotheobservation group(43 cases)and thecontrol group(42 cases)according to the random number table method.The control group received Fluorouracil and Oxaliplatin treatment,and the observation group received Oxaliplatin and Capecitabine treatment.The clinical efficacy,serum tumor marker levels,immune function and adverse reactions were compared between the two groups.Results The clinical response rate in the observation group was 67.44%,which was higher than that in the control group(42.86%),the difference was statistically significant(P＜0.05).The level of CA125([43.09±5.63]μg/ml)and CA199([67.39±7.42]μg/ml)in the observation group after chemotherapy were lower than those in the control group ([58.61±4.81]μg/ml,[83.75±9.58]μg/ml),the level of CD4+([36.79±4.53]%),CD4+/CD8+([1.32±0.43])in the observation group after chemotherapy were higher than those in the control group([31.24±4.85]%,[1.11±0.39]),the differences were statistically significant(P＜0.05).There was no significant difference in the level of CD8+between the two groups before and after chemotherapy(P＞0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of Capecitabine and Oxaliplatin in the treatment of advanced colorectal cancer can improve the short-term efficacy,improve the immune function of patients,adjust the level of serum tumor markers,and have fewer adverse reactions.It is an effective and relatively safe chemotherapy in the treatment of advanced colorectal cancer.
京公网安备 11010502046607号